{{Rsnum
|rsid=7270101
|Gene=ITPA
|Chromosome=20
|position=3213247
|Orientation=plus
|GMAF=0.07392
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
|Gene_s=ITPA
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;C)
| geno3=(C;C)
| CEU | 74.3 | 25.7 | 0.0
| HCB | 100.0 | 0.0 | 0.0
| JPT | 100.0 | 0.0 | 0.0
| YRI | 81.6 | 16.3 | 2.0
| ASW | 0.0 | 0.0 | 0.0
| CHB | 100.0 | 0.0 | 0.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 96.0 | 3.0 | 1.0
| LWK | 77.1 | 20.2 | 2.8
| MEX | 89.7 | 10.3 | 0.0
| MKK | 70.5 | 27.6 | 1.9
| TSI | 79.4 | 19.6 | 1.0
| HapMapRevision=28
}}{{PMID Auto
|PMID=20637204
|Title=ITPA Polymorphism Affects Ribavirin-induced Anemia and Outcome of Therapy - a Genome-wide Study of Japanese HCV Patients
}}

{{omim
|id=147520
|rsnum=7270101
}}

{{omim
|id=609532
|rsnum=7270101
}}

{{PMID Auto
|PMID=21274861
|Title=Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR
}}

{{PMID Auto
|PMID=22118055
|Title=Single and combined IL28B, ITPA and SLC28A3 host genetic markers modulating response to anti-hepatitis C therapy
}}

{{PMID Auto
|PMID=22272297
|Title=Erythrocyte Inosine Triphosphatase Activity Is Decreased in HIV-Seropositive Individuals
|OA=1
}}

{{PMID Auto
|PMID=21703177
|Title=Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients
|OA=1
}}

{{PMID Auto
|PMID=22584257
|Title=Genetic variants at the ITPA locus protect against ribavirin-induced hemolytic anemia and dose reduction in an HCV G2/G3 cohort.
}}

{{PMID Auto
|PMID=18662289
|Title=Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine.
|OA=1
}}

{{PMID Auto
|PMID=20547162
|Title=Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction.
|OA=1
}}

{{PMID Auto
|PMID=22028438
|Title=Impact of inosine triphosphatase gene variants on the risk of anemia in HIV/hepatitis C virus-coinfected patients treated for chronic hepatitis C.
}}

{{PMID Auto
|PMID=22158703
|Title=Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes.
|OA=1
}}

{{PMID Auto
|PMID=22406654
|Title=Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment.
}}

{{PMID Auto
|PMID=22430973
|Title=Association of ITPA gene polymorphisms and the risk of ribavirin-induced anemia in HIV/hepatitis C virus (HCV)-coinfected patients receiving HCV combination therapy.
|OA=1
}}

{{PMID Auto
|PMID=22613675
|Title=Comparison of three different methods for the evaluation of IL28 and ITPA polymorphisms in patients infected with HCV.
}}

{{PMID Auto
|PMID=23195617
|Title=Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infection
}}

{{PMID Auto GWAS
  |PMID=20173735
  |Trait=Chronic Hepatitis C infection
  |Title=ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.
  |RiskAllele=C
  |Pval=9E-76
  |OR=NR
  |ORtxt=NR
  }}

{{PMID Auto
|PMID=23933495
|Title=Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients
}}

{{PMID Auto
|PMID=22585729
|Title=ITPA gene polymorphisms significantly affect hemoglobin decline and treatment outcomes in patients coinfected with HIV and HCV.
|OA=1
}}

{{PMID Auto
|PMID=23133602
|Title=Pharmacogenetics of efficacy and safety of HCV treatment in HCV-HIV coinfected patients: significant associations with IL28B and SOCS3 gene variants.
|OA=1
}}

{{PMID Auto
|PMID=23201294
|Title=Allelic inhibition of displacement activity: a simplified one tube allele-specific PCR for evaluation of ITPA polymorphisms.
}}

{{PMID Auto
|PMID=24304455
|Title=Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy
}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Illumina Human 1M}}